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EDITORIALSugar-Coated Proteins Pave the Way to Improving Pancreatic
Cancer Diagnosisancreatic ductal adenocarcinoma (PDAC) is a deadlyPmalignancy with an overall 5-year survival rate of
7%. By contrast, stage IA PDAC is associated with a 5-year
survival rate of 40% after resection, underscoring the
beneﬁts of early diagnosis in conjunction with surgical
intervention. Unfortunately, the vast majority of patients do
not present with early PDAC, and approximately 80% of
patients have metastatic or locally advanced cancer at
clinical presentation, which preclude the possibility of
curative resection. Key reasons for the late diagnosis
of PDAC include the absence of symptoms or the presence of
only vague symptoms in early disease, difﬁculties inherent
in diagnostic imaging of the pancreas, and the absence of
sensitive and speciﬁc diagnostic markers in the circulation.
Serum carbohydrate antigen 19-9 (CA19-9) is the only
PDAC serum biomarker approved for clinical use by the
Food and Drug Administration. CA19-9 is a glycan, and more
speciﬁcally a sialylated lacto-N-fucopentaose II glycan that
is related to the Lewis (a) antigen. Glycans are poly-
saccharides that attach to glycoproteins and glycolipids.
O-linked glycans are attached to serine and threonine resi-
dues through O-linked N-acetylgalactosamine, and are
abundant in mucins, whereas N-linked glycans are attached
to the amide group of asparagine residues in proteins.
Cancer can be associated with aberrant glycan structure and
glycosylation that can, in turn, lead to altered function and
generation of cancer-speciﬁc epitopes that can be useful
diagnostically. Although antibodies against CA19-9 gener-
ally recognize the sialyl-Lewis A (sLeA) antigen, which may
be expressed at high levels in PDAC, this marker lacks both
sensitivity and speciﬁcity; is not expressed in approximately
14% of the general population, is not increased in approx-
imately 25% of patients with PDAC, and serum CA19-9 level
may be increased in patients with hyperbilirubinemia
without PDAC.
In the article by Tang et al1 in this issue of Cellular and
Molecular Gastroenterology and Hepatology, the in-
vestigators proﬁled the levels of multiple glycans and mucin
glycoforms in plasma from 200 subjects with either PDAC or
benign pancreatic disease, and validated selected ﬁndings in
subsequent cohorts totaling 216 subjects. They found sig-
niﬁcant increases in glycans that are distinct from sLeA.
Because glycans are carried by glycoproteins, and CA19-9 is
carried by a variety of glycoproteins, including MUC5AC and
MUC1, Tang et al1 examined MUC5AC glycoforms and
determined that in addition to sLeA, MUC5AC carried sialyl-
Lewis X, a previously described isomer of sLeA, and sialyl-
LacNAc type 1. They also assessed sulfated and sialylated
variants of sLeA/sLeX. Impressively, the serum levels each
of the other glycans performed as well as sLeA levels whenCellular and Molecular Gastroenterology and Hepatology 2016;2:118–1used as individual markers and were increased in distinct
groups of patients. Moreover, the 3-marker panel provided
85% sensitivity and 90% speciﬁcity in the combined dis-
covery and validation cohorts, by contrast to 54% sensi-
tivity and 86% speciﬁcity for sLeA. The same 3-marker
panel also yielded 80% sensitivity and 84% speciﬁcity in the
independent test cohort. It remains to be determined
whether the 3-marker panel also will be useful for moni-
toring PDAC recurrence and patient prognosis.
Each of these glycan markers was increased in some
PDAC patients but not in others, leading Tang et al1 to
suggest that in addition to the utility of the 3-marker panel
for improving the diagnosis of PDAC, comparison of sLeA-
related glycans with CA19-9 could facilitate PDAC subclas-
siﬁcation. It also is possible that this subclassiﬁcation
represents a broader approach than measuring individual
proteins. For example, proteins such as CD44 and MUC1
carry sLeA glycans, and proteins such as Kras, SPARC, and
Wnt7b express Lewis X glycans.2 Although all of these
proteins have been implicated in PDAC, glycan-based sub-
classiﬁcation may offer greater power than analysis of in-
dividual proteins. In addition, some heparan sulfate
proteoglycans are expressed aberrantly in PDAC, and the
heparan sulfate proteoglycan glypican-1 has been shown to
contribute to PDAC progression in a genetically engineered
mouse model of PDAC.3 Thus, glycan-coated proteins clearly
have an important role in PDAC pathobiology, and the cur-
rent ﬁndings underscore the importance of advancing our
knowledge of the role of glycans in PDAC. Of course, further
study is required to determine whether glycan-based sub-
classiﬁcation is useful. Nonetheless, these and other data
show that tools such as genomics, epigenomics, proteomics,
metabolomics, and glycomics are important for proﬁling
cancers. The present ﬁndings also raise the possibility that
the expression of speciﬁc glycans within the pancreatic tu-
mor mass, their presence in serum, and their possible ability
to circulate within exosomes, especially given the known
presence of CA19-9 in exosomes and the potential of PDAC-
released exosomes to facilitate distal metastases, could help
guide precision medicine strategies that maximize thera-
peutic beneﬁts in PDAC.
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